Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%KO-0.71%0700.HK-6.35%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.84%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-2.43%UNH-10.21%1288.HK-1.71%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.59%EURAUD+1.01%AUDCAD-1.00%AUDCHF-1.00%GBPAUD+0.95%AUDNZD-0.95%NZDJPY-0.77%GBPJPY-0.75%EURJPY-0.72%CADJPY-0.70%CHFJPY-0.70%AUDSGD-0.64%NZDUSD-0.64%GBPUSD-0.62%USDCHF+0.62%USDCAD+0.60%EURUSD-0.59%AUDDKK-0.57%USDZAR+0.48%GBPTRY+0.41%AUDNOK-0.40%USDMXN+0.39%NZDMXN+0.35%USDTHB+0.32%GBPHKD+0.32%EURZAR+0.32%USDNOK+0.31%GBPZAR+0.30%GBPMXN-0.28%CHFNOK+0.24%NOKJPY-0.23%USDSEK+0.22%USDTRY+0.21%USDPLN+0.20%EURCNH-0.18%EURNOK+0.16%EURHKD-0.16%USDILS+0.16%CHFSEK+0.15%USDDKK+0.15%USDJPY-0.13%USDCNH-0.12%PLNJPY-0.10%GBPSGD-0.09%EURSGD-0.08%EURSEK+0.08%USDSGD+0.07%NZDCAD-0.07%EURPLN+0.05%NZDCHF-0.05%GBPCAD-0.05%EURNZD+0.05%EURGBP+0.05%NZDSGD+0.04%USDCOP-0.04%EURCZK+0.04%SGDJPY+0.03%EURCHF+0.03%CADCHF+0.02%USDHKD-0.02%GBPNZD+0.02%GBPCHF-0.01%CHFSGD-0.01%EURCAD0.00%EURDKK0.00%XPTUSD-1.03%XAGUSD-0.70%GAGUSD-0.70%HG1-0.63%W1-0.55%GAUUSD-0.52%XAUUSD-0.52%XNGUSD-0.42%C1-0.40%S1-0.18%UKOIL+0.17%USOIL-0.12%BTCUSD-3.42%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.24%XLMUSD-3.75%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.88%TONUSD+59.18%HBARUSDT-5.17%TAOUSDT-3.05%AAVEUSD-3.31%ONDOUSDT-5.19%ICPUSDT-2.22%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.51%ATOMUSDT-2.31%INJUSDT-7.34%STXUSDT-3.10%PYTHUSDT-0.66%TIAUSDT-3.10%FETUSDT-4.54%JUPUSDT-0.13%SEIUSDT-4.48%GRTUSDT-3.25%OPUSDT-3.90%IOTAUSDT-2.39%POLUSDT-1.98%WIFUSDT-2.98%AXSUSDT-2.76%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.86%GALAUSDT-2.38%DYDXUSDT-2.73%ORDIUSDT-2.46%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.47%KO-0.71%0700.HK-6.35%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.84%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.70%0857.HK-2.43%UNH-10.21%1288.HK-1.71%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.69%AUDUSD-1.59%EURAUD+1.01%AUDCAD-1.00%AUDCHF-1.00%GBPAUD+0.95%AUDNZD-0.95%NZDJPY-0.77%GBPJPY-0.75%EURJPY-0.72%CADJPY-0.70%CHFJPY-0.70%AUDSGD-0.64%NZDUSD-0.64%GBPUSD-0.62%USDCHF+0.62%USDCAD+0.60%EURUSD-0.59%AUDDKK-0.57%USDZAR+0.48%GBPTRY+0.41%AUDNOK-0.40%USDMXN+0.39%NZDMXN+0.35%USDTHB+0.32%GBPHKD+0.32%EURZAR+0.32%USDNOK+0.31%GBPZAR+0.30%GBPMXN-0.28%CHFNOK+0.24%NOKJPY-0.23%USDSEK+0.22%USDTRY+0.21%USDPLN+0.20%EURCNH-0.18%EURNOK+0.16%EURHKD-0.16%USDILS+0.16%CHFSEK+0.15%USDDKK+0.15%USDJPY-0.13%USDCNH-0.12%PLNJPY-0.10%GBPSGD-0.09%EURSGD-0.08%EURSEK+0.08%USDSGD+0.07%NZDCAD-0.07%EURPLN+0.05%NZDCHF-0.05%GBPCAD-0.05%EURNZD+0.05%EURGBP+0.05%NZDSGD+0.04%USDCOP-0.04%EURCZK+0.04%SGDJPY+0.03%EURCHF+0.03%CADCHF+0.02%USDHKD-0.02%GBPNZD+0.02%GBPCHF-0.01%CHFSGD-0.01%EURCAD0.00%EURDKK0.00%XPTUSD-1.03%XAGUSD-0.70%GAGUSD-0.70%HG1-0.63%W1-0.55%GAUUSD-0.52%XAUUSD-0.52%XNGUSD-0.42%C1-0.40%S1-0.18%UKOIL+0.17%USOIL-0.12%BTCUSD-3.42%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.76%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.24%XLMUSD-3.75%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.88%TONUSD+59.18%HBARUSDT-5.17%TAOUSDT-3.05%AAVEUSD-3.31%ONDOUSDT-5.19%ICPUSDT-2.22%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.51%ATOMUSDT-2.31%INJUSDT-7.34%STXUSDT-3.10%PYTHUSDT-0.66%TIAUSDT-3.10%FETUSDT-4.54%JUPUSDT-0.13%SEIUSDT-4.48%GRTUSDT-3.25%OPUSDT-3.90%IOTAUSDT-2.39%POLUSDT-1.98%WIFUSDT-2.98%AXSUSDT-2.76%EOSUSDT-4.24%IMXUSDT-3.36%FARTCOINUSDT-6.86%GALAUSDT-2.38%DYDXUSDT-2.73%ORDIUSDT-2.46%NOTUSDT-2.34%RONINUSDT-2.92%
RM

Revolution Medicines, Inc. (RVMD)

NASDAQ • Healthcare

$159.82
-$2.87 (-1.8%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$162.35
Day Range$158.41 - $163.04
Avg. Volume (3M)2.3M
Market Cap$34.5B
52 Week Range
$69.5$224.31

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$197.5M100%
Gross Profitminus cost of goods$197.2M100%

Fundamentals & Financials

Revenue (TTM)
$197.5M
Net Income (TTM)
-$1.8B
EPS (TTM)
-$9.15
ROA (TTM)
-43.47%
Current Ratio
8.36

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-24.5%Q2 2026-$2.29
-50.0%Q3 2026-$3.06
+19.1%Q4 2026-$1.9

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +19.1%

Revolution Medicines topped consensus EPS expectations in the third fiscal quarter of 2026, reported November 4, 2026, with EPS of -$1.90 topping the -$2.35 estimate by $0.45, while net income was a loss of roughly $407.5 million, down 33.5% year over year and versus a loss of about $305.2 million a year ago. Revenue came in at about $197.6 million, supporting gross profit of roughly $197.2 million and a gross margin of ~100%, while operating results remained deeply negative with operating income of around -$373.1 million and an operating margin of roughly -189%. EPS was down 18.0% year over year (from -$1.61 a year ago), tracking the wider net loss for the period as the clinical-stage precision oncology pipeline, including programs such as RMC-4630, RMC-5845, and RMC-5552, continued to drive operating spend ahead of marketed product revenue. For the next period, consensus calls for EPS of -$1.90 on revenue of $184.0 million.

View full earnings history

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology biotechnology company listed on NASDAQ as RVMD. The company develops targeted cancer medicines aimed at pathways central to RAS-driven tumors, and its work centers on a pipeline of inhibitors designed for specific signaling proteins and mutation states rather than marketed products.

Name
Revolution Medicines, Inc.
CEO
Mark A. Goldsmith
Industry
Healthcare
Year Founded
2014
Employees
883

Today's Snapshot

AI-generated

The day ended with RVMD 1.8% lower at 159.82, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level. Revolution Medicines won European approval for Rasonque, its pancreatic-cancer drug.

Trading Volume

Below 10d avg (3.3M)

2.2M

vs S&P 500 Today

Underperforming Market

-1.50%

Updated: November 18, 2026 at 21:17 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
RVMD shows persistent selling pressure with momentum and trend indicators aligned bearish: RSI is low, MACD is negative and medium-term moving averages sit well above the current price, leaving the market below its short- and medium-term structure and marginally under the 200-day pivot. ATR signals elevated volatility and OBV reflects net selling, while ADX indicates only a moderate trend strength, suggesting the move lacks strong acceleration. The pivot lies above the market and confirms resistance. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$157.22 - $188.29
    Sell
  • RSI (14)34.16
    Neutral
  • Stochastic %K (14, 3, 3)2.27
    Buy
  • MACD Level (12, 26)-7.15
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.